Myriad Genetics Launches Precise MRD Test with One-in-Million Sensitivity
Myriad Genetics has launched its tumor-informed Precise MRD test for breast cancer patients through select community oncology practices, enabling ultrasensitive ctDNA detection down to one part per million. The company plans a broader U.S. rollout of the assay later this year, targeting longitudinal treatment monitoring and personalized therapy decisions.
1. Initial Launch Details
Myriad Genetics has launched the Precise MRD test in a limited commercial release with select community oncology practices for breast cancer patients, with no cap on participating patients during this initial phase.
2. Test Technology
The tumor-informed ctDNA assay uses whole-genome sequencing to create a personalized panel for each patient, enabling ultrasensitive detection of circulating tumor DNA down to one part per million.
3. Commercialization Outlook
The company plans to expand the Precise MRD test to a broader U.S. rollout later this year, aiming to drive adoption in community settings and potentially boost future diagnostic testing revenues.